

## Dracorhodin perchlorate Datasheet

5<sup>th</sup> Edition (Revised in January, 2017)

### [ Product Information ]

**Name:** Dracorhodin perchlorate

**Catalog No.:** CFN90486

**Cas No.:** 125536-25-6


**Purity:** >=98%

**M.F:** C<sub>17</sub>H<sub>15</sub>ClO<sub>7</sub>

**M.W:** 366.75

**Physical Description:** Red powder

**Synonyms:** Methane,5-methoxy-6-methyl-2-phenylchromenylium-7-ol.



### [ Intended Use ]

1. Reference standards;
2. Pharmacological research;
3. Synthetic precursor compounds;
4. Intermediates & Fine Chemicals;
5. Others.

### [ Source ]

The herbs of *Daemonorops draco* Bl.

### [ Biological Activity or Inhibitors ]

Dracorhodin perchlorate can inhibit PI3K/Akt and NF-κB activation, up-regulate the

expression of p53, and enhance apoptosis in cancer cells <sup>[1]</sup>

Dracorhodin perchlorate alters the intracellular redox status, changes the balance of Bcl-X(L) and Bax protein expression, and induces apoptosis through caspase pathways in HeLa cells.<sup>[2]</sup>

Dracorhodin perchlorate can inhibit high glucose-induced connective tissue growth factor expression in human mesangial cells, and this may be its mechanism of prevention and treatment on renal fibrosis in diabetic nephropathy (DN). <sup>[3]</sup>

Dracorhodin perchlorate has been used as a medicine to treat chronic wounds, the effects of it on wound healing have association with the Ras/MAPK signaling pathway.<sup>[4]</sup>

## **[ Solvent ]**

Pyridine, Methanol, Ethanol, etc.

## **[ HPLC Method ]<sup>[5]</sup>**

Mobile phase: Acetonitrile-0.05 M Sodium dihydrogen phosphate solution=37:63 ;

Flow rate: 1.0 ml/min;

Column temperature: 30 °C;

The wave length of determination: 440 nm.

## **[ Storage ]**

2-8°C, Protected from air and light, refrigerate or freeze.

## **[ References ]**

[1] Rasul A, Ding C, Li X, et al. *Apoptosis*, 2012, 17(10):1104-19.

[2] Xia M, Wang D, Wang M, et al. *J. Pharmacol.Sci.*, 2004, 95(2):273-83.

[3] Wang Y H, Wang Q S, Liu J G, et al. *Zhongguo Zhong yao za zhi*, 2009, 34(7):896-9.

[4] Li F, Jiang T, Liu W, et al. *Mol. Med. Rep.*, 2016, 14(2):1667-72.

[5] He Y, Ding N, Wang R Z, et al. *Journal of Chinese Pharmaceutical Sciences*, 2015,

50(2):120-4.

## **[ Contact ]**

**Address:**

S5-3 Building, No. 111, Dongfeng Rd.,  
Wuhan Economic and Technological Development Zone,  
Wuhan, Hubei 430056,  
China

**Email:** [info@chemfaces.com](mailto:info@chemfaces.com)

**Tel:** +86-27-84237783

**Fax:** +86-27-84254680

**Web:** [www.chemfaces.com](http://www.chemfaces.com)

**Tech Support:** [service@chemfaces.com](mailto:service@chemfaces.com)